Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Phys Med Biol ; 2024 Jun 11.
Article in English | MEDLINE | ID: mdl-38862000

ABSTRACT

OBJECTIVE: In proton pencil beam scanning (PBS) continuous delivery, the beam is continuously delivered without interruptions between spots. For synchrotron-based systems, the extracted beam current exhibits a spill structure, and recent publications on beam current measurements have demonstrated significant fluctuations around the nominal values. These fluctuations potentially lead to dose deviations from those calculated assuming a stable beam current. This study investigated the dosimetric implications of such beam current fluctuations during proton PBS continuous scanning. Approach: Using representative clinical proton PBS plans, we performed simulations to mimic a worst-case clinical delivery environment with beam current varies from 50% to 250% of the nominal values. The simulations used the beam delivery parameters optimized for the best beam delivery efficiency of the upcoming particle therapy system at Mayo Clinic Florida. We reconstructed the simulated delivered dose distributions and evaluated the dosimetric impact of beam current fluctuations. Main results: Despite significant beam current fluctuations resulting in deviations at each spot level, the overall dose distributions were nearly identical to those assuming a stable beam current. The 1mm/1% Gamma passing rate was 100% for all plans. Less than 0.2% root mean square error (RMSE) was observed in the PTV DVH. Minimal differences were observed in all dosimetric evaluation metrics. Significance: Our findings demonstrate that with our beam delivery system and clinical planning practice, while significant beam current fluctuations may result in large local move MU deviations at each spot level, the overall impact on the dose distribution is minimal. .

2.
Phys Med Biol ; 69(11)2024 May 30.
Article in English | MEDLINE | ID: mdl-38714191

ABSTRACT

Objective.This study aims to address the limitations of traditional methods for calculating linear energy transfer (LET), a critical component in assessing relative biological effectiveness (RBE). Currently, Monte Carlo (MC) simulation, the gold-standard for accuracy, is resource-intensive and slow for dose optimization, while the speedier analytical approximation has compromised accuracy. Our objective was to prototype a deep-learning-based model for calculating dose-averaged LET (LETd) using patient anatomy and dose-to-water (DW) data, facilitating real-time biological dose evaluation and LET optimization within proton treatment planning systems.Approach. 275 4-field prostate proton Stereotactic Body Radiotherapy plans were analyzed, rendering a total of 1100 fields. Those were randomly split into 880, 110, and 110 fields for training, validation, and testing. A 3D Cascaded UNet model, along with data processing and inference pipelines, was developed to generate patient-specific LETddistributions from CT images and DW. The accuracy of the LETdof the test dataset was evaluated against MC-generated ground truth through voxel-based mean absolute error (MAE) and gamma analysis.Main results.The proposed model accurately inferred LETddistributions for each proton field in the test dataset. A single-field LETdcalculation took around 100 ms with trained models running on a NVidia A100 GPU. The selected model yielded an average MAE of 0.94 ± 0.14 MeV cm-1and a gamma passing rate of 97.4% ± 1.3% when applied to the test dataset, with the largest discrepancy at the edge of fields where the dose gradient was the largest and counting statistics was the lowest.Significance.This study demonstrates that deep-learning-based models can efficiently calculate LETdwith high accuracy as a fast-forward approach. The model shows great potential to be utilized for optimizing the RBE of proton treatment plans. Future efforts will focus on enhancing the model's performance and evaluating its adaptability to different clinical scenarios.


Subject(s)
Deep Learning , Linear Energy Transfer , Proton Therapy , Radiotherapy Planning, Computer-Assisted , Proton Therapy/methods , Humans , Radiotherapy Planning, Computer-Assisted/methods , Monte Carlo Method , Radiotherapy Dosage , Male
3.
Int J Radiat Oncol Biol Phys ; 117(4): 846-856, 2023 Nov 15.
Article in English | MEDLINE | ID: mdl-37244627

ABSTRACT

PURPOSE: To report oncologic, physician-assessed, and patient-reported outcomes (PROs) for a group of women homogeneously treated with modern, skin-sparing multifield optimized pencil-beam scanning proton (intensity modulated proton therapy [IMPT]) postmastectomy radiation therapy (PMRT). METHODS AND MATERIALS: We reviewed consecutive patients who received unilateral, curative-intent, conventionally fractionated IMPT PMRT between 2015 and 2019. Strict constraints were applied to limit the dose to the skin and other organs at risk. Five-year oncologic outcomes were analyzed. Patient-reported outcomes were evaluated as part of a prospective registry at baseline, completion of PMRT, and 3 and 12 months after PMRT. RESULTS: A total of 127 patients were included. One hundred nine (86%) received chemotherapy, among whom 82 (65%) received neoadjuvant chemotherapy. The median follow-up was 4.1 years. Five-year locoregional control was 98.4% (95% CI, 93.6-99.6), and overall survival was 87.9% (95% CI, 78.7-96.5). Acute grade 2 and 3 dermatitis was seen in 45% and 4% of patients, respectively. Three patients (2%) experienced acute grade 3 infection, all of whom had breast reconstruction. Three late grade 3 adverse events occurred: morphea (n = 1), infection (n = 1), and seroma (n = 1). There were no cardiac or pulmonary adverse events. Among the 73 patients at risk for PMRT-associated reconstruction complications, 7 (10%) experienced reconstruction failure. Ninety-five patients (75%) enrolled in the prospective PRO registry. The only metrics to increase by >1 point were skin color (mean change: 5) and itchiness (2) at treatment completion and tightness/pulling/stretching (2) and skin color (2) at 12 months. There was no significant change in the following PROs: bleeding/leaking fluid, blistering, telangiectasia, lifting, arm extension, or bending/straightening the arm. CONCLUSIONS: With strict dose constraints to skin and organs at risk, postmastectomy IMPT was associated with excellent oncologic outcomes and PROs. Rates of skin, chest wall, and reconstruction complications compared favorably to previous proton and photon series. Postmastectomy IMPT warrants further investigation in a multi-institutional setting with careful attention to planning techniques.

4.
J Appl Clin Med Phys ; 24(7): e13973, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36972299

ABSTRACT

PURPOSE: Proton treatment plan perturbation by common dental fixtures such as amalgams (Am) and porcelain-fused-to-metal (PFM) crowns has, to date, been uncharacterized. Previous studies have been conducted to determine the physical effect of these materials within the beam path for single spots, but their effects on complex treatment plans and clinical anatomy have not yet been quantified. The present manuscript aims to study the effect of Am and PFM fixtures on proton treatment planning in a clinical setting. METHODS: An anthropomorphic phantom with removable tongue, maxilla, and mandible modules was simulated on a clinical computed tomography (CT) scanner. Spare maxilla modules were modified to include either a 1.5 mm depth central groove occlusal amalgam (Am) or a porcelain-fused-to-metal (PFM) crown, implanted on the first right molar. Modified tongue modules were 3D printed to accommodate several axial or sagittal oriented pieces of EBT-3 film. Clinically representative spot-scanning proton plans were generated in Eclipse v.15.6 using the proton convolution superposition (PCS) algorithm v.15.6.06 using a multi-field optimization (MFO) technique with the goal of delivering a uniform 54 Gy dose to a clinical target volume (CTV) typical of a base-of-tongue (BoT) treatment. A typical geometric beam arrangement of two anterior oblique (AO) beams and a posterior beam was employed. Plans optimized without any material overrides were delivered to the phantom A) without implants; B) with Am fixture; or C) with PFM crown. Plans were also reoptimized and delivered with inclusion of material overrides to equate relative stopping power of the fixture with that of a previously measured result. RESULTS: Plans exhibit slightly greater dose weight towards AO beams. The optimizer accounted for inclusion of fixture overrides by increasing beam weights to the beam closest to the implant. Film measurements exhibited cold spots directly within the beam path through the fixture in plans with and without overridden materials. Cold spots were somewhat mitigated in plans including overridden materials in the structure set but were not entirely eliminated. Cold spots associated with Am and PFM fixtures were quantified at 17% and 14% for plans without overrides, respectively, and 11% and 9% with using Monte Carlo simulation. Compared with film measurements and Monte Carlo simulation, the treatment planning system underestimates the dose shadowing effect in plans including material overrides. CONCLUSIONS: Dental fixtures create a dose shadowing effect directly in line with the beam path through the material. This cold spot is partially mitigated by overriding the material to measured relative stopping powers. Due to uncertainties in modeling perturbation through the fixture, the magnitude of the cold spot is underestimated using the institutional TPS when compared to measurement and MC simulation.


Subject(s)
Proton Therapy , Radiotherapy, Intensity-Modulated , Humans , Proton Therapy/methods , Protons , Radiotherapy Dosage , Dental Porcelain , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methods , Monte Carlo Method
5.
Med Phys ; 50(1): 600-618, 2023 Jan.
Article in English | MEDLINE | ID: mdl-35986907

ABSTRACT

BACKGROUND: Although intensity-modulated radiation therapy and volumetric arc therapy have revolutionized photon external beam therapies, the technological advances associated with electron beam therapy have fallen behind. Modern linear accelerators contain technologies that would allow for more advanced forms of electron treatments, such as beam collimation, using the conventional photon multi-leaf collimator (MLC); however, no commercial solutions exist that calculate dose from such beam delivery modes. Additionally, for clinical adoption to occur, dose calculation times would need to be on par with that of modern dose calculation algorithms. PURPOSE: This work developed a graphics processing unit (GPU)-accelerated Monte Carlo (MC) engine incorporating the Varian TrueBeam linac head geometry for a rapid calculation of electron beams collimated using the conventional photon MLC. METHODS: A compute unified device architecture framework was created for the following: (1) transport of electrons and photons through the linac head geometry, considering multiple scattering, Bremsstrahlung, Møller, Compton, and pair production interactions; (2) electron and photon propagation through the CT geometry, considering all interactions plus the photoelectric effect; and (3) secondary particle cascades through the linac head and within the CT geometry. The linac head collimating geometry was modeled according to the specifications provided by the vendor, who also provided phase-space files. The MC was benchmarked against EGSnrc/DOSXYZnrc/GEANT by simulating individual interactions with simple geometries, pencil, and square beam dose calculations in various phantoms. MC-calculated dose distributions for MLC and jaw-collimated electron fields were compared to measurements in a water phantom and with radiochromic film. RESULTS: Pencil and square beam dose distributions are in good agreement with DOSXYZnrc. Angular and spatial distributions for multiple scattering and secondary particle production in thin slab geometries are in good agreement with EGSnrc and GEANT. Dose profiles for MLC and jaw-collimated 6-20-MeV electron beams showed an average absolute difference of 1.1 and 1.9 mm for the FWHM and 80%-20% penumbra from measured profiles. Percent depth doses showed differences of <5% for as compared to measurement. The computation time on an NVIDIA Tesla V100 card was 2.5 min to achieve a dose uncertainty of <1%, which is ∼300 times faster than published results in a similar geometry using a single-CPU core. CONCLUSIONS: The GPU-based MC can quickly calculate dose for electron fields collimated using the conventional photon MLC. The fast calculation times will allow for a rapid calculation of electron fields for mixed photon and electron particle therapy.


Subject(s)
Electrons , Radiotherapy, Intensity-Modulated , Algorithms , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated/methods , Radiotherapy Planning, Computer-Assisted/methods , Phantoms, Imaging , Particle Accelerators , Monte Carlo Method , Photons
6.
Pract Radiat Oncol ; 12(5): e442-e452, 2022.
Article in English | MEDLINE | ID: mdl-35417782

ABSTRACT

PURPOSE: Our purpose was to dosimetrically compare volumetric modulated arc therapy (VMAT) lattice radiation therapy (LRT), brass, and proton grid therapy planning techniques and suggest potential clinical applications for each. METHODS AND MATERIALS: Four plans delivering 20 Gy in 1 fraction were created for each of 22 patients. Brass and proton grid plans used a single static field and the same beam angle. Proton grid plans used the same beam size and spacing as the brass block. Two VMAT LRT plans were generated for each patient: one with 1-cm diameter lattice points spaced 2-cm center-to-center (2-cm VMAT) and another with 1.5-cm diameter lattice points spaced 3-cm center-to-center (3- cm VMAT). Maximum, minimum, mean, and equivalent uniform dose and the dose to 90%, 50%, 20%, 10%, and 5% (D90%[%], D50%[%], etc) of gross tumor volume (GTV) were reported. D10%/D90% characterized dose heterogeneity. Normal tissue dose was generalized by the maximum dose and volume in cubic centimeters of tissue outside the GTV receiving 30% and 50% of prescription (body-GTV V30%[cm3]; body-GTV V50%[cm3]). RESULTS: VMAT LRT plans delivered the highest maximum GTV doses while brass and proton plans delivered higher D5%(%), D10%(%), and D20%(%) values. D50%(%), D90%(%), and minimum dose varied little between plan types. Proton and brass plans had the highest dose heterogeneity. Two-centimeter VMAT and brass grid plans had the highest mean GTV doses. Two-centimeter VMAT plans had the highest equivalent uniform dose, followed by 3-cm VMAT, brass, and proton plans. VMAT LRT plans exhibited the lowest normal tissue maximum and body GTV V30%(cm3) and body GTV V50%(cm3) values. CONCLUSIONS: An in-depth comparison of target and normal tissue dosimetric parameters for common photon and proton grid therapy planning techniques was made. Strengths of each plan type were noted leading to general recommendations on usage.


Subject(s)
Proton Therapy , Radiotherapy, Intensity-Modulated , Copper , Humans , Organs at Risk , Proton Therapy/methods , Protons , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methods , Zinc
7.
Med Phys ; 49(5): 2904-2913, 2022 May.
Article in English | MEDLINE | ID: mdl-35276753

ABSTRACT

PURPOSE: Dental fixtures are commonplace in an aging, radiation treatment population. The current, local standard of practice in particle therapy is to employ treatment geometries to avoid delivery through implanted dental fixtures. The present study aims to observe the physical effect of delivering therapeutic proton beams through common dental fixture materials as prelude to an eventual goal of assessing the feasibility of using treatment geometries not specified for avoidance of oral implants. A sampling of common dental materials was selected based on prosthodontic consult and was evaluated in terms of relative stopping power and three-dimensional (3D) dose perturbation. METHODS: Amalgams, porcelain-fused-to-metal (PFM) crowns consisting of zirconia and non-noble base metals, and lithium disilicate implants were chosen for analysis. Theoretical stopping power (S) and mass stopping power (S/ρ) were calculated using the Stopping and Range of Ions in Matter (SRIM) application, basing stoichiometric compositions of each fixture on published materials data. S and S/ρ were calculated for a range of historically available compositions of amalgams from 1900 until the current era. The perturbance of S and S/ρ as a function of clinically relevant ranges of amalgam compositions for the modern era was analyzed. Water equivalent thickness (WET) and relative stopping power (Srel ) of each material was measured for a clinical spot-scanning proton beam with monoenergies of 159.9 and 228.8 MeV with a multi-layer ionization chamber (MLIC). Subsequently, 3D dose perturbation was assessed by delivering proton beams through a custom phantom designed to simulate both en-face and on-edge treatment geometries through the selected materials. A treatment plan mimicking the experimental delivery was constructed in the institutional treatment planning system and calculated using TOPAS-based Monte Carlo simulation (MCS). Experimental results were used to validate the MCS. Finally, treatment planning system (TPS) outputs were compared to MCS to determine the accuracy of the dose calculation model. RESULTS: Historical compositions of amalgams ranged in S from 44.8 to 42.9 MeV/cm, with the greatest deviation being observed for the 1900-1959 era. Deviation as a function of amalgam composition from the modern era was most sensitive to proportion of Hg, accounting for deviations up to -4.2% at the greatest clinically relevant concentration. S/ρ was not found to vary greatly between each porcelain and metal alloy material for PFM type crowns. Relative stopping powers ranged between 1.3 and 5.4 for all studied materials, suggesting substantial changes in proton range with respect to water. Film measurements of pristine spots confirm dose perturbance and shortening of proton range, with an upstream shift of each Bragg peak being observed directly behind the installed fixture. At high energies, cold spots were found in all cases directly behind each material feature with a medial fill-in of dose occurring distally. Qualitative agreement of spot perturbance was confirmed between film measurements and MCS. Finally, when comparing integrated depth doses (IDD) by summing over all axial directions, good agreement is observed between TPS and MCS. CONCLUSIONS: All dental materials studied substantially perturbed the dosimetry of pristine proton spots both in terms of WET/Srel as well as the spatial distribution of dose. Proton range was quantifiably shortened, and each dental material affected a cold spot directly behind the object with medial dose back-filling was observed distally. MCS and Eclipse dose calculations exhibited good agreement with measurements, suggesting that treatment planning without employing avoidance strategies may be possible with further investigation.


Subject(s)
Proton Therapy , Protons , Dental Porcelain , Monte Carlo Method , Proton Therapy/methods , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Water
8.
Crit Rev Food Sci Nutr ; 62(1): 272-281, 2022.
Article in English | MEDLINE | ID: mdl-32951433

ABSTRACT

Three-dimensional (3D) printing is a fast-developing digital technology with colossal market scope in food and nutrition technology, providing a platform for establishing unique food products with enhanced sensory and nutritional value for a particular end-user. Cultured meat is the concept of producing meat sustainably in laboratory conditions without the sacrifice of animal life and the excessive use of antibiotics. 3D printing could offer unique solutions for the vital issues of cultured meat production; particularly on regulating the protein, fat, and other nutritional content, along with providing realistic texture. This review highlights the immense benefits of 3D printing technology for the scalable and reproducible production of cultured meat products.


Subject(s)
Meat Products , Animals , Meat , Nutritional Status , Printing, Three-Dimensional
9.
Fam Process ; 61(4): 1663-1680, 2022 12.
Article in English | MEDLINE | ID: mdl-34921397

ABSTRACT

This study examines the 21-year longitudinal impacts and predictive effects of family caregiver transition and the presence of family caregiving on the clinical status of persons with schizophrenia (PwSs) in a rural area of China. Using panel data derived from the Chengdu Mental Health Project (CMHP), 250 dyads of PwSs and their family caregivers were investigated in 1994 and 2015. The Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF) were utilized. The generalized linear model (GLM) approach was used. The results of this study showed that more severe symptoms in PwSs were found to be significantly predicted by older age and nonmarried status at baseline. Compared with "spousal caregiving in two waves," the PANSS score was significantly higher in the "transition into sibling caregiving" group. A higher degree of psychosocial functioning was found to be significantly predicted by marital status, shorter duration of illness, and better mental status. Compared with "spousal caregiving in two waves," the GAF score was significantly lower in the "transition into parental caregiving" group. The presence of family caregiving was not a significant predictor of the severity of symptoms or psychosocial functioning in the PwSs. In conclusion, this study shows the 21-year predictive effects of family caregiver transition on the mental status of PwSs but not the presence of family caregiving. Psychosocial interventions and specific guidance should be provided to family caregivers to enhance their quality of caregiving and improve the prognosis of PwSs during long periods of home care.


En este estudio se analizan los efectos longitudinales a 21 años y los efectos pronósticos de la transición de los cuidadores familiares y la presencia de cuidado familiar en el estado clínico de las personas con esquizofrenia en un área rural de China. Utilizando datos de panel extraídos del Proyecto de salud mental de Chengdu (Chengdu Mental Health Project, CMHP), se investigaron 250 díadas de personas con esquizofrenia y sus cuidadores familiares en 1994 y 2015. Se utilizó la Escala de síndrome positivo y negativo (Positive and Negative Syndrome Scale, PANSS) y la Evaluación global del funcionamiento (Global Assessment of Functioning, GAF). También se utilizó el método de modelo lineal generalizado. Los resultados de este estudio demostraron que los síntomas más intensos en las personas con esquizofrenia fueron pronosticados principalmente por la edad avanzada y el estado de soltería en el momento basal. En comparación con el grupo de "cuidado de los cónyuges en dos intervalos", el puntaje de la PANSS fue considerablemente más alto en el grupo de "transición al cuidado de los hermanos". Se descubrió que principalmente el estado civil, la duración más corta de la enfermedad y un mejor estado mental pronosticaron un grado más alto de funcionamiento psicosocial. En comparación con el grupo de "cuidado de los cónyuges en dos intervalos", el puntaje de la GAF fue considerablemente más bajo en el grupo de "transición al cuidado de los padres". La presencia de cuidado familiar no fue un factor pronóstico importante de la intensidad de los síntomas ni del funcionamiento psicosocial en las personas con esquizofrenia. En resumen, en este estudio se muestran los efectos pronósticos a 21 años de la transición de los cuidadores familiares en el estado mental de las personas con esquizofrenia, pero no la presencia de cuidado familiar. Deben ofrecerse intervenciones psicosociales y orientación específica a los cuidadores familiares para mejorar su calidad de cuidado y mejorar el pronóstico de las personas con esquizofrenia durante los periodos prolongados de cuidado en el hogar.


Subject(s)
Caregivers , Schizophrenia , Humans , China
10.
Preprint in English | bioRxiv | ID: ppbiorxiv-446272

ABSTRACT

Anti-viral small molecules are currently lacking for treating coronavirus infection. The long development timescales for such drugs are a major problem, but could be shortened by repurposing existing drugs. We therefore screened a small library of FDA-approved compounds for potential severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antivirals using a pseudovirus system that allows a sensitive read-out of infectivity. A group of structurally-related compounds, showing moderate inhibitory activity with IC50 values in the 1-5{micro}M range, were identified. Further studies demonstrated that these kite-shaped molecules were surprisingly specific for SARS-CoV and SARS-CoV-2 and that they acted early in the entry steps of the viral infectious cycle, but did not affect virus attachment to the cells. Moreover the compounds were able to prevent infection in both kidney- and lung-derived human cell lines. The structural homology of the hits allowed the production of a well-defined pharmacophore that was found to be highly accurate in predicting the anti-viral activity of the compounds in the screen. We discuss the prospects of repurposing these existing drugs for treating current and future coronavirus outbreaks.

11.
J Transl Med ; 19(1): 154, 2021 04 15.
Article in English | MEDLINE | ID: mdl-33858444

ABSTRACT

BACKGROUND: During intrauterine development, the formation and function of synaptic vesicles (SVs) are thought to be fundamental conditions essential for normal development of the brain. Lacking advanced technology during the intrauterine period, such as longitudinal real-time monitoring of the SV-associated transcripts (SVATs), which include six pairs of lncRNA-mRNA, has limited acquisition of the dynamic gene expression profile (GEP) of SVATs. We previously reported the differential expression of SVATs in the peripheral blood of autistic children. The current study was designed to determine the dynamic profiles of differentially-expressed SVATs in circulating exosomes (EXs) derived from autistic children and pregnant women at different gestational ages. METHODS: Blood samples were collected from autistic children and women with variant physiopathologic pregnancies. EXs were isolated with an ExoQuick Exosome Precipitation Kit and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blotting. The expression of lncRNAs and lncRNA-targeted mRNAs were quantified using real-time PCR. RESULTS: SVAT-associated lncRNAs-mRNAs were detected in autistic children and differentially expressed from the first trimester of pregnancy to the term of delivery. Pathologic pregnancies, including spontaneous preterm birth (sPTB), preeclampsia (PE), and gestational diabetes mellitus (GDM), were compared to normal physiologic pregnancies, and shown to exhibit specific correlations between SVAT-lncRNA and SVAT-mRNA of STX8, SLC18A2, and SYP with sPTB; SVAT-lncRNA and SVAT-mRNA of STX8 with PE; and SVAT-lncRNA and SVAT-mRNA of SV2C as well as SVAT-mRNA of SYP with GDM. CONCLUSION: Variant complications in pathologic pregnancies may alter the GEP of SVATs, which is likely to affect the intrauterine development of neural circuits and consequently influence fetal brain development.


Subject(s)
Autistic Disorder , Exosomes , Pre-Eclampsia , Premature Birth , Autistic Disorder/genetics , Child , Exosomes/genetics , Female , Humans , Infant, Newborn , Pregnancy , Synaptic Vesicles
12.
Int J Radiat Oncol Biol Phys ; 110(5): 1383-1395, 2021 08 01.
Article in English | MEDLINE | ID: mdl-33771703

ABSTRACT

PURPOSE: Our previous work demonstrated that 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) positron emission tomography (PET) is sensitive and specific for identifying regions of high density and biologically aggressive glioblastoma. The purpose of this prospective phase 2 study was to determine the safety and efficacy of biologic-guided, dose-escalated radiation therapy (DERT) using 18F-DOPA PET in patients with glioblastoma. METHODS AND MATERIALS: Patients with newly diagnosed, histologically confirmed glioblastoma aged ≥18 years without contraindications to 18F-DOPA were eligible. Target volumes included 51, 60, and 76 Gy in 30 fractions with a simultaneous integrated boost, and concurrent and adjuvant temozolomide for 6 months. 18F-DOPA PET imaging was used to guide DERT. The study was designed to detect a true progression-free survival (PFS) at 6 months (PFS6) rate ≥72.5% in O6-methylguanine methyltransferase (MGMT) unmethylated patients (DE-Un), with an overall significance level (alpha) of 0.20 and a power of 80%. Kaplan-Meier analysis was performed for PFS and overall survival (OS). Historical controls (HCs) included 139 patients (82 unmethylated) treated on prospective clinical trials or with standard RT at our institution. Toxicities were evaluated with Common Terminology Criteria for Adverse Events v4.0. RESULTS: Between January 2014 and December 2018, 75 evaluable patients were enrolled (39 DE-Un, 24 methylated [DE-Mth], and 12 indeterminate). PFS6 for DE-Un was 79.5% (95% confidence interval, 63.1%-90.1%). Median PFS was longer for DE-Un patients compared with historical controls (8.7 months vs 6.6 months; P = .017). OS was similarly longer, but the difference was not significant (16.0 vs 13.5 months; P = .13). OS was significantly improved for DE-Mth patients compared with HC-Mth (35.5 vs 23.3 months; P = .049) despite nonsignificant improvement in PFS (10.7 vs 9.0 months; P = .26). Grade 3 central nervous system necrosis occurred in 13% of patients, but treatment with bevacizumab improved symptoms in all cases. CONCLUSIONS: 18F-DOPA PET-guided DERT appears to be safe, and it significantly improves PFS in MGMT unmethylated glioblastoma. OS is significantly improved in MGMT methylated patients. Further investigation of 18F-DOPA PET biologic guided DERT for glioblastoma is warranted.


Subject(s)
Brain Neoplasms/radiotherapy , Dihydroxyphenylalanine/analogs & derivatives , Glioblastoma/radiotherapy , Positron-Emission Tomography , Radiopharmaceuticals , Radiotherapy, Image-Guided , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Alkylating/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Bevacizumab/therapeutic use , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Chemotherapy, Adjuvant/methods , Cognition/radiation effects , Confidence Intervals , Dose Fractionation, Radiation , Female , Glioblastoma/diagnostic imaging , Glioblastoma/drug therapy , Glioblastoma/mortality , Humans , Kaplan-Meier Estimate , Male , Methylation , Middle Aged , O(6)-Methylguanine-DNA Methyltransferase/metabolism , Progression-Free Survival , Prospective Studies , Quality of Life , Temozolomide/therapeutic use , Young Adult
13.
Psychol Med ; : 1-9, 2021 Feb 23.
Article in English | MEDLINE | ID: mdl-33618792

ABSTRACT

BACKGROUND: Although poverty associated with severe mental illness (SMI) has been documented in many studies, little long-term evidence of social drift exists. This study aimed to unravel the poverty transitions among persons with SMI in a fast change community in China. METHODS: Two mental health surveys, using the International Classification of Disease (ICD-10), were conducted in the same six townships of Xinjin county, Chengdu, China in 1994 and 2015. A total of 308 persons with SMI identified in 1994 were followed up in 2015. The profiles of poverty transitions were identified and regression modelling methods were applied to determine the predictive factors of poverty transitions. RESULTS: The poverty rate of persons with SMI increased from 39.9% to 49.4% in 1994 and 2015. A larger proportion of them had fallen into poverty (27.3%) rather than moved out of it (17.8%). Those persons with SMI who had lost work ability, had physical illness and more severe mental disabilities in 1994, as well as those who had experienced negative changes on these factors were more likely to live in persistent poverty or fall into poverty. Higher education level and medical treatment were major protective factors of falling into poverty. CONCLUSIONS: This study shows long-term evidence on the social drift of persons with SMI during the period of rapid social development in China. Further targeted poverty alleviation interventions should be crucial for improving treatment and mental recovery and alleviating poverty related to SMI.

14.
Habitat Int ; 103: 102204, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32834300

ABSTRACT

There have been increasing concerns about neighbourhoods' contextual characteristics and the importance of applying integrated sustainability principles to develop sustainable neighbourhoods. Among the contextual characteristics, the role of residents' perception of their neighbourhoods is critical when identifying various local sustainability issues and developing sustainable neighbourhood planning. However, little research has been done on evaluating residents' subjective perceptions of different neighbourhoods' sustainability performance, particularly in this time of transitional China. Thus, this research employed an empirical approach to investigate residents' perceived sustainability performance in three different neighbourhoods, including the traditional danwei, resettlement and commodity housing neighbourhoods in Chengdu. Questionnaire surveys and expert interviews were conducted to analyse the sustainability performance and critical sustainability issues in different neighbourhoods. The results demonstrated that infrastructure and public engagement were two common and significant factors affecting the sustainability of all three neighbourhoods. Most importantly, the three different neighbourhoods showed different sustainability challenges which called for developing contextual framework for sustainable neighbourhood development. Several theoretical and policy implications for planning were also provided.

15.
Phys Med Biol ; 65(15): 155020, 2020 07 31.
Article in English | MEDLINE | ID: mdl-32590359

ABSTRACT

To develop a Monte Carlo (MC)-based and robust ion beam therapy optimization system that separates the optimization algorithm from the relative biological effectiveness (RBE) modeling. Robustly optimized dose distributions were calculated and compared across three ion therapy beams (proton, helium, carbon). The effect of different averaging techniques in calculating RBE in mixed beams was also investigated. Ion particles were transported in TOPAS MC. The microdosimetric-kinetic model (MKM) parameter, saturation corrected specific energy ([Formula: see text]), was calculated with a customized MKM implementation in TOPAS MC. Intensity modulated ion therapy robust optimization was performed by a quasi-Newton iterative method based on dose-volume objective function. The robust optimization took setup and range uncertainties into account. In the present work, the biological dose for each individual spot was calculated, and then summed together to calculate total biological dose. In other published works, radiosensitive parameters, such as [Formula: see text], were first averaged over all beam spots within a mixed-beam field, after which biological dose was calculated using the averaged radiosensitive parameters. The difference between the two mixed-beam biological dose calculations was quantified. Robust plans were achieved with the three particle types. The effect of averaging [Formula: see text] depended on particle type. The difference between biological doses calculated with individual [Formula: see text] and averaged [Formula: see text] may be greater than 3% for a carbon beam. MC based radiobiological and robust optimization was made flexible to incorporate dose-volume histogram constraints and to be independent of RBE models. Iterative optimization with RBE models was feasible. Evaluation of the RBE calculation for mixed beam could be necessary if better accuracy was demanded.


Subject(s)
Models, Biological , Monte Carlo Method , Radiobiology , Radiometry , Radiotherapy/methods , Algorithms , Helium/therapeutic use , Humans , Kinetics , Relative Biological Effectiveness , Uncertainty
16.
Aquat Toxicol ; 222: 105469, 2020 May.
Article in English | MEDLINE | ID: mdl-32179334

ABSTRACT

Phthalates are commonly used in plastic products in daily life. The endocrine-disrupting effects of phthalates have been widely reported. Accumulating evidence from human cohorts and lab animals indicate exposure to phthalates might impair neurodevelopment. However, the direct causal relationship and mechanism between phthalates with neurodevelopment and neurotoxicity have not been firmly established. We found that phthalates (i.e. DBP, DINP, BBP) disrupted the expression of estrogen receptors (esr1, esr2a, esr2b), and impaired neurogenesis in the brain of zebrafish during embryonic development. Moreover, the abnormal expression of estrogen receptors, especially esr2a, was partly rescued in zebrafish which exposed to phthalates, with the estrogen receptor antagonist tamoxifen. Hence, impaired neurogenesis of zebrafish exposed to phthalates was partly reversed by tamoxifen treatment. Moreover, our results show that induced pluripotent stem cells (iPSC)-derived human neurons exposed to phthalates triggered double-strand DNA breaks in vitro. Overall, this study demonstrates that exposure to phthalates affects neurodevelopment in zebrafish embryos and induces neurotoxicity in human neurons partly through disrupting the expression of estrogen receptors.


Subject(s)
DNA Breaks, Double-Stranded , Embryonic Development/drug effects , Endocrine Disruptors/toxicity , Neurons/drug effects , Phthalic Acids/toxicity , Receptors, Estrogen/genetics , Water Pollutants, Chemical/toxicity , Animals , Cells, Cultured , Embryo, Nonmammalian/drug effects , Embryonic Development/genetics , Estrogen Receptor Antagonists/pharmacology , Humans , Neurons/metabolism , Neurons/pathology , Zebrafish
17.
Pract Radiat Oncol ; 10(2): e71-e81, 2020.
Article in English | MEDLINE | ID: mdl-31494289

ABSTRACT

PURPOSE: The relative biologic effectiveness (RBE) rises with increasing linear energy transfer toward the end of proton tracks. Presently, there is no consensus on how RBE heterogeneity should be accounted for in breast cancer proton therapy treatment planning. Our purpose was to determine the dosimetric consequences of incorporating a brachial plexus (BP) biologic dose constraint and to describe other clinical implications of biologic planning. METHODS AND MATERIALS: We instituted a biologic dose constraint for the BP in the context of MC1631, a randomized trial of conventional versus hypofractionated postmastectomy intensity modulated proton therapy (IMPT). IMPT plans of 13 patients treated before the implementation of the biologic dose constraint (cohort A) were compared with IMPT plans of 38 patients treated on MC1631 after its implementation (cohort B) using (1) a commercially available Eclipse treatment planning system (RBE = 1.1); (2) an in-house graphic processor unit-based Monte Carlo physical dose simulation (RBE = 1.1); and (3) an in-house Monte Carlo biologic dose (MCBD) simulation that assumes a linear relationship between RBE and dose-averaged linear energy transfer (product of RBE and physical dose = biologic dose). RESULTS: Before implementation of a BP biologic dose constraint, the Eclipse mean BP D0.01 cm3 was 107%, and the MCBD estimate was 128% (ie, 64 Gy [RBE = biologic dose] in 25 fractions for a 50-Gy [RBE = 1.1] prescription), compared with 100.0% and 116.0%, respectively, after the implementation of the constraint. Implementation of the BP biologic dose constraint did not significantly affect clinical target volume coverage. MCBD plans predicted greater internal mammary node coverage and higher heart dose than Eclipse plans. CONCLUSIONS: Institution of a BP biologic dose constraint may reduce brachial plexopathy risk without compromising target coverage. MCBD plan evaluation provides valuable information to physicians that may assist in making clinical judgments regarding relative priority of target coverage versus normal tissue sparing.


Subject(s)
Brachial Plexus Neuropathies/etiology , Breast Neoplasms/complications , Proton Therapy/methods , Relative Biological Effectiveness , Adult , Aged , Brachial Plexus Neuropathies/pathology , Female , Humans , Middle Aged , Monte Carlo Method , Prospective Studies
18.
Int J Radiat Oncol Biol Phys ; 105(3): 664-673, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31301328

ABSTRACT

PURPOSE: To evaluate the incidence of imaging changes in our pediatric brain tumor population treated with spot-scanning proton therapy and analyze the spatial correlation of imaging changes with a novel biologic dose model. METHODS AND MATERIALS: All pediatric patients treated during the first year of our institution's experience who received a minimum treatment planning dose (TPD) of 5040 cGyE with available follow-up magnetic resonance imaging scans were selected for analysis. Posttreatment magnetic resonance imaging scans were fused with the treatment planning computed tomography. All T1 post-gadolinium enhancement, T2 fluid attenuated inversion recovery changes, TPD, and biologic dose (BD) volumes outside of the original gross tumor volume were contoured for analysis. RESULTS: Thirty patients were included in the analysis, 7 of whom developed posttreatment radiologic changes. The volumetric overlap of the T2 fluid attenuated inversion recovery changes and BD volumes was significantly greater than the overlap with the TPD volumes. Median volumetric overlaps of 85%, 18%, and 0% were observed with the BD105%, BD110%, and TPD105%, respectively. A nonsignificant increase in the volumetric overlap of the T1C+ changes and BD volumes was also observed. No correlation was observed between the total volume of BD110%, BD105%, or physical dose 105% and the development of imaging changes. CONCLUSIONS: Within our pediatric brain tumor population treated with spot-scanning proton therapy, our BD model demonstrated superior volumetric overlap with posttreatment T2 changes compared with the TPD model. Using a BD model in treatment planning for spot-scanning proton therapy may help avoid delivery of excessive BD to critical structures and may help minimize the risk of radiation-related late effects.


Subject(s)
Brain Neoplasms/diagnostic imaging , Brain Neoplasms/radiotherapy , Magnetic Resonance Imaging , Multimodal Imaging/methods , Proton Therapy/methods , Tomography, X-Ray Computed , Adolescent , Analysis of Variance , Brain Neoplasms/pathology , Child , Child, Preschool , Female , Gadolinium , Humans , Infant , Magnetic Resonance Imaging/methods , Male , Monte Carlo Method , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Retrospective Studies , Tumor Burden
19.
PLoS One ; 14(2): e0212412, 2019.
Article in English | MEDLINE | ID: mdl-30763390

ABSTRACT

The purpose of this work was to develop an end-to-end patient-specific quality assurance (QA) technique for spot-scanned proton therapy that is more sensitive and efficient than traditional approaches. The patient-specific methodology relies on independently verifying the accuracy of the delivered proton fluence and the dose calculation in the heterogeneous patient volume. A Monte Carlo dose calculation engine, which was developed in-house, recalculates a planned dose distribution on the patient CT data set to verify the dose distribution represented by the treatment planning system. The plan is then delivered in a pre-treatment setting and logs of spot position and dose monitors, which are integrated into the treatment nozzle, are recorded. A computational routine compares the delivery log to the DICOM spot map used by the Monte Carlo calculation to ensure that the delivered parameters at the machine match the calculated plan. Measurements of dose planes using independent detector arrays, which historically are the standard approach to patient-specific QA, are not performed for every patient. The nozzle-integrated detectors are rigorously validated using independent detectors in regular QA intervals. The measured data are compared to the expected delivery patterns. The dose monitor reading deviations are reported in a histogram, while the spot position discrepancies are plotted vs. spot number to facilitate independent analysis of both random and systematic deviations. Action thresholds are linked to accuracy of the commissioned delivery system. Even when plan delivery is acceptable, the Monte Carlo second check system has identified dose calculation issues which would not have been illuminated using traditional, phantom-based measurement techniques. The efficiency and sensitivity of our patient-specific QA program has been improved by implementing a procedure which independently verifies patient dose calculation accuracy and plan delivery fidelity. Such an approach to QA requires holistic integration and maintenance of patient-specific and patient-independent QA.


Subject(s)
Patient-Specific Modeling , Proton Therapy/methods , Quality Assurance, Health Care/methods , Algorithms , Humans , Monte Carlo Method , Neoplasms/diagnostic imaging , Neoplasms/radiotherapy , Proton Therapy/standards , Proton Therapy/statistics & numerical data , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Retrospective Studies
20.
Phys Med Biol ; 64(5): 055015, 2019 03 07.
Article in English | MEDLINE | ID: mdl-30673655

ABSTRACT

Radiochromic film (RCF) is a valuable dosimetric tool, primarily due to its sub-millimeter spatial resolution. For accurate proton dosimetry, the dependence of film response on linear energy transfer (LET) must be characterized and calibrated. In this work, we characterized film under-response, or 'quenching', as a function of dose-weighted linear energy transfer (LETd) in several proton fields and established a simple, linear relationship with LETd. We performed measurements as a function of depth in a PMMA phantom irradiated by a spot-scanning proton beam. The fields had energies of 71.3 MeV, 71.3 MeV with filter, and 159.9 MeV. At each depth (measurements taken in depth step sizes of 0.5-1 mm in the Bragg peak), we measured dose with a PTW Markus ion chamber and EBT3 RCF. EBT3 under-response was characterized by the ratio of dose measured with film to that with ion chamber. LETd values for our experimental setup were calculated using in-house clinical Monte Carlo code. Measured film under-response increased with LETd, from approximately 10% under-response for LETd = 5 keV µm-1 to approximately 20% for LETd = 8 keV µm-1. The under-response for all measurements was plotted versus LETd. A linear fit to the data was performed, yielding a function for under-response, [Formula: see text], with respect to LETd: [Formula: see text]. Finally, the linear under-response relationship was applied to a film measurement within a spread-out Bragg peak (SOBP). Without correcting for LETd-dependence in the SOBP measurement, the discrepancy between film and Monte Carlo profiles was greater than 15% at the distal edge. With correction, the corrected film profile was within 2% and 1 mm of the Monte Carlo profile. RCF response depends on LETd, potentially under-responding by >15% in clinically-relevant scenarios. Therefore, it is insufficient to perform only a dose calibration; LET calibration is also necessary for accurate proton film dosimetry. The LETd-dependence of EBT3 can be described by a single, linear function over a range of clinically-relevant proton therapy LETd values.


Subject(s)
Film Dosimetry/methods , Linear Energy Transfer , Proton Therapy/methods , Algorithms , Calibration , Computer Simulation , Humans , Linear Models , Monte Carlo Method , Phantoms, Imaging , Polymethyl Methacrylate
SELECTION OF CITATIONS
SEARCH DETAIL
...